Tag: LDL

1. In individuals aged 70-100 years, there was a significantly increased risk of myocardial infarction and atherosclerotic cardiovascular disease for every 1.0 mmol/L increase in LDL cholesterol. 2. Individuals aged 80-100 years were found to have the lowest number needed to treat in 5 years to prevent one myocardial infarction. Evidence...

 1. In patients aged ≥75 years, LDL cholesterol-lowering therapies reduced the risk for major vascular events, including cardiovascular death, myocardial infarction, stroke, and coronary revascularization. 2. In older patients (≥75 years), the benefits in risk reduction were similar when compared to younger patients (< 75 years), and when comparing statin...

1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did not demonstrate additional serious adverse events compared to the control group. Evidence Rating Level: 1 (Excellent) Study Rundown: Homozygous familial hypercholesterolemia occurs due to a loss-of-function variant in the low-density lipoprotein (LDL)...

1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did not demonstrate additional serious adverse events compared to the control group. Evidence Rating Level: 1 (Excellent) Study Rundown: Homozygous familial hypercholesterolemia occurs due to a loss-of-function variant in the low-density lipoprotein (LDL)...

Click to read the study in JAHA Image: PD ©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the...

1. Inclisiran, a small interfering RNA, therapy was shown to significantly lower levels of low-density lipoprotein (LDL) cholesterol compared to the placebo in adults with heterozygous familial hypercholesterolemia. 2. The reduction in LDL cholesterol levels, via inclisiran therapy, was shown to be similar to the reduction achieved with proprotein convertase...

1. Inclisiran, a small interfering RNA, therapy was shown to significantly lower levels of low-density lipoprotein (LDL) cholesterol compared to the placebo in adults with heterozygous familial hypercholesterolemia. 2. The reduction in LDL cholesterol levels, via inclisiran therapy, was shown to be similar to the reduction achieved with proprotein convertase...

1. This randomized controlled trial showed that patients with ischemic stroke or transient ischemic attack with target LDL levels of less than 70 mg/dL had lower rates of subsequent cardiovascular events when compared to target LDL levels of 90 to 110 mg/dL.  2. Patients were provided with a statin and...

1. This randomized controlled trial showed that patients with ischemic stroke or transient ischemic attack with target LDL levels of less than 70 mg/dL had lower rates of subsequent cardiovascular events when compared to target LDL levels of 90 to 110 mg/dL.  2. Patients were provided with a statin and...